BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 35095878)

  • 21. Prospective, open, multicentre Phase I/II trial to assess safety and efficacy of neoadjuvant radiochemotherapy with docetaxel and cisplatin for esophageal carcinoma.
    Ma HB; Di ZL; Wen J; Ke Y; Sun X; Ren J
    Jpn J Clin Oncol; 2015 Feb; 45(2):169-75. PubMed ID: 25416813
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Docetaxel and cisplatin: an active regimen in patients with locally advanced, recurrent or metastatic squamous cell carcinoma of the head and neck. Results of a phase II study of the EORTC Early Clinical Studies Group.
    Schöffski P; Catimel G; Planting AS; Droz JP; Verweij J; Schrijvers D; Gras L; Schrijvers A; Wanders J; Hanauske AR
    Ann Oncol; 1999 Jan; 10(1):119-22. PubMed ID: 10076732
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neoadjuvant toripalimab combined with gemcitabine and cisplatin in resectable locally advanced head and neck squamous cell carcinoma (NeoTGP01): An open label, single-arm, phase Ib clinical trial.
    Huang X; Liu Q; Zhong G; Peng Y; Liu Y; Liang L; Hong H; Feng W; Yang S; Zhang Y; Xian S; Li Z; Zhou Y; Zhang Z; Jiang W; Liang J; Liu ZG
    J Exp Clin Cancer Res; 2022 Oct; 41(1):300. PubMed ID: 36224603
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Atezolizumab plus modified docetaxel-cisplatin-5-fluorouracil (mDCF) regimen versus mDCF in patients with metastatic or unresectable locally advanced recurrent anal squamous cell carcinoma: a randomized, non-comparative phase II SCARCE GERCOR trial.
    Kim S; Buecher B; André T; Jary M; Bidard FC; Ghiringhelli F; François É; Taieb J; Smith D; de la Fouchardière C; Desramé J; Samalin E; Parzy A; Baba-Hamed N; Bouché O; Tougeron D; Dahan L; El Hajbi F; Jacquin M; Rebucci-Peixoto M; Spehner L; Vendrely V; Vernerey D; Borg C
    BMC Cancer; 2020 Apr; 20(1):352. PubMed ID: 32334548
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Variation of PD-L1 expression in locally advanced cervical cancer following neoadjuvant chemotherapy.
    Liang Y; Yu M; Zhou C; Zhu X
    Diagn Pathol; 2020 Jun; 15(1):67. PubMed ID: 32493336
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Analysis on efficacy and safety of total neoadjuvant therapy in patients with locally advanced rectal cancer with high risk factors].
    Ouyang GL; Meng WJ; Shu P; Deng XB; Wu B; Jiang D; Zhuang H; Shen YL; Zhou ZG; Wang ZQ; Wang X
    Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Apr; 22(4):349-356. PubMed ID: 31054549
    [No Abstract]   [Full Text] [Related]  

  • 27. [Phase Ⅱ clinical trial of PD-1 inhibitor combined with chemotherapy for locally advanced resectable oral squamous cell carcinoma].
    Wang HL; Yue K; Wu YS; Duan YS; Jing C; Wang XD
    Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2024 Apr; 59(4):335-342. PubMed ID: 38599641
    [No Abstract]   [Full Text] [Related]  

  • 28. Combined chemoradiation therapy for anal cancer. A report of 56 cases.
    Doci R; Zucali R; Bombelli L; Montalto F; Lamonica G
    Ann Surg; 1992 Feb; 215(2):150-6. PubMed ID: 1546901
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Squamous cell carcinoma of the anal margin: the university of Florida experience.
    Balamucki CJ; Zlotecki RA; Rout WR; Newlin HE; Morris CG; Kirwan JM; George TJ; Mendenhall WM
    Am J Clin Oncol; 2011 Aug; 34(4):406-10. PubMed ID: 20881476
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Short-course neoadjuvant radiotherapy combined with chemotherapy and toripalimab for locally advanced esophageal squamous cell carcinoma (SCALE-1): a single-arm phase Ib clinical trial.
    Jiang N; Zhang J; Guo Z; Wu Y; Zhao L; Kong C; Song X; Gu L; Zhao Y; Li S; He X; Ren B; Zhu X; Jiang M
    J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38199609
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Induction chemoimmunotherapy followed by CD8+ immune cell-based patient selection for chemotherapy-free radioimmunotherapy in locally advanced head and neck cancer.
    Hecht M; Eckstein M; Rutzner S; von der Grün J; Illmer T; Klautke G; Laban S; Hautmann MG; Brunner TB; Tamaskovics B; Hinke A; Zhou JG; Frey B; Donaubauer AJ; Becker I; Semrau S; Hartmann A; Balermpas P; Budach W; Gaipl US; Iro H; Gostian AO; Fietkau R
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35078923
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neoadjuvant chemotherapy followed by radiotherapy in epidermoid carcinoma of anus.
    Chie EK; Wu HG; Heo DS; Bang YJ; Kim NK; Ha SW
    Tumori; 2004; 90(3):299-302. PubMed ID: 15315309
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Phase II Study of Capecitabine/Oxaliplatin With Concurrent Radiotherapy in Locally Advanced Squamous Cell Carcinoma of the Anal Canal.
    Eng C; Jácome AA; Das P; Chang GJ; Rodriguez-Bigas M; Skibber JM; Wolff RA; Qiao W; Xing Y; Sethi S; Ohinata A; Crane CH
    Clin Colorectal Cancer; 2019 Dec; 18(4):301-306. PubMed ID: 31350201
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neoadjuvant PD-1 Plus Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma.
    Qian T; Liu D; Cao G; Chen Z; Zhang Q
    Technol Cancer Res Treat; 2024; 23():15330338241231610. PubMed ID: 38497137
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neoadjuvant Programmed Cell Death 1 (PD-1) Inhibitor Treatment in Patients With Hepatocellular Carcinoma Before Liver Transplant: A Cohort Study and Literature Review.
    Qiao ZY; Zhang ZJ; Lv ZC; Tong H; Xi ZF; Wu HX; Chen XS; Xia L; Feng H; Zhang JJ; Xia Q
    Front Immunol; 2021; 12():653437. PubMed ID: 34349755
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neoadjuvant programmed cell death 1 blockade combined with chemotherapy for resectable esophageal squamous cell carcinoma.
    Yang W; Xing X; Yeung SJ; Wang S; Chen W; Bao Y; Wang F; Feng S; Peng F; Wang X; Chen S; He M; Zhang N; Wang H; Zeng B; Liu Z; Kidane B; Seder CW; Koyanagi K; Shargall Y; Luo H; Peng S; Cheng C
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35022193
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase 1 study of cetuximab in combination with 5-fluorouracil, cisplatin, and radiotherapy in patients with locally advanced anal canal carcinoma.
    Olivatto LO; Vieira FM; Pereira BV; Victorino AP; Bezerra M; Araujo CM; Erlich F; Faroni L; Castro L; Lusis EC; Marins A; Ferreira CG
    Cancer; 2013 Aug; 119(16):2973-80. PubMed ID: 23674135
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neoadjuvant TPF in locally advanced head and neck cancer can be followed by radiotherapy combined with cisplatin or cetuximab: a study of 157 patients.
    Fayette J; Bonnin N; Ferlay C; Lallemant B; Ramade A; Favrel V; Zrounba P; Chabaud S; Pommier P; Poupart M; Céruse P
    Anticancer Drugs; 2013 Jul; 24(6):623-9. PubMed ID: 23542750
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pilot study of FMC (5-fluorouracil, mitomycin C, and cisplatin) with radiotherapy for patients with anal cancer.
    Lee IH; Lee SJ; Kang BW; Chae YS; Baek D; Hwang S; Kim HJ; Park SY; Park JS; Choi GS; Kim JC; Kim JG
    Cancer Chemother Pharmacol; 2016 Dec; 78(6):1263-1267. PubMed ID: 27830320
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neoadjuvant docetaxel, cisplatin and ifosfamide (ITP) combination chemotherapy for treating penile squamous cell carcinoma patients with terminal lymph node metastasis.
    Xu J; Li G; Zhu SM; Cai QL; Wang Z; Yang X; Zhang HT; Niu YJ
    BMC Cancer; 2019 Jun; 19(1):625. PubMed ID: 31238987
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.